Imovane (Zopiclone)

Zopiclone acts as a positive allosteric modulator at the benzodiazepine binding site of the GABA_A receptor. By enhancing GABA‑mediated chloride influx, it increases neuronal inhibition, producing a calming effect that facilitates sleep initiation and maintenance.

The appropriate dose of Imovane is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal function, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Zopiclone in pregnancy or while breastfeeding has not been firmly established. It should only be used if the potential benefit justifies the potential risk, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Imovane product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imovane (Zopiclone) belongs to the cyclopyrrolone class, offering a rapid onset of action and a relatively short half‑life compared with many benzodiazepines. This profile can reduce next‑day residual sedation, but individual response and safety considerations differ among agents, so clinicians choose based on patient needs and risk factors.

Imovane tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Imovane is taken orally, usually as a whole tablet, shortly before bedtime. Patients should swallow the tablet with a glass of water and avoid taking it with or after a heavy meal that might delay absorption.

Serious risks include severe allergic reactions, mood changes such as depression or suicidal thoughts, abnormal behaviors like sleep‑walking or hallucinations, and respiratory depression when combined with other central nervous system depressants.

Imovane is contraindicated in individuals with known hypersensitivity to Zopiclone or any cyclopyrrolone, patients with severe hepatic impairment, and those who have experienced complex sleep‑related behaviors with similar agents. Caution is also advised for the elderly and patients with a history of substance misuse.